Brevan Howard Capital Management’s Aura Biosciences AURA Stock Holding History

Brevan Howard Capital Management’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$199K	Buy	+29,746	New	+$171K	﹤0.01%	1897

Other funds holding AURA

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Brevan Howard Capital Management's AURA Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Aura Biosciences (AURA) in Q1 2026: 29,746 shares worth $199K. The stake represents ﹤0.01% of the portfolio and ranks #1897 among its holdings.

126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

Brevan Howard Capital Management held 29,746 shares of Aura Biosciences worth $199K as of Q1 2026.
Aura Biosciences was a new Brevan Howard Capital Management position in Q1 2026.
Aura Biosciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1897 holding.
126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.